Autologous immune-cell therapy practiced in Japan, helping Vinmec Hospital after technology transfer
16/10/2022
Technology transfer on cell therapy to Vietnam by GN Corporation leads to new opportunities
Press release
Webiner on “Cell Therapy Approaches for Urethral Stricture” jointly held with Edogawa Hospital
1/10/2022
Webiner on Cell Therapy Approaches for Urethral Stricture is held on 16 OCt 2022
Paper on Potential of Beta-Glucan Products to Prevent and Treat Non-Alcoholic Fatty Liver Disease
1/10/2022
A look at the potential of beta-glucan for the growing number of non-alcoholic fatty liver diseases
Tackling long COVID-19, with safety proven Japanese Beta Glucans; The first clinical report in the world
8/10/2021
Paper on potential of beta glucan products is pubrished
Path-breaking feat of reversing in-vitro aging of human chondrocytes; published in Nature Journal
10/7/2021
The paper is published in Scientific Reports, Nature Journal
New Advances in Regenerative Treatments for Cartilage Injuries Published in THE KNEE
11/3/2021
GNC succeeded in culturing hyaluronic acid-rich chondrocytes in a 3D tissue engineering platform.
News
GN Corporation hosted a Morning seminar on Neu REFIX at the AOMC-JMS 2024 conference at Nara, Japan
6/10/2024
Neu REFIX pre-clinical studies in mdx mice @ AOMC-JMS 2024
Thoothukudi Medical College Dermatologists unravel a novel solution for Psoriasis Vulgaris using Neu-REFIX Beta glucan jointly with Japanese scientists.
4/7/2024
At the MENA Conference on Rare DiData presented in IFPA 7th World Psoriasis conference, in Stockholm, Sweden 0
“neu REFIX ” potentials in Duchenne Muscular Dystrophy will be presented at MENA Rare Diseases Conference in UAE
19/4/2024
“neu REFIX ” potentials in Duchenne Muscular Dystrophy will be